

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (MODIFIED)

ATTORNEY'S DOCKET NUMBER
X-11634**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5)

09/744432INTERNATIONAL APPLICATION NO.
PCT/US99/16937INTERNATIONAL FILING
DATE
July 26, 1999 (07/26/99)PRIORITY DATE CLAIMED
July 31, 1998 (07/31/98)

TITLE OF INVENTION: CRYOGRANULATION OF ACTIVATED PROTEIN C

APPLICANT(S) FOR DO/EO/US: Jeffrey Clayton Baker, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
- ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) 09/744432	INTERNATIONAL APPLICATION NO. PCT/US99/16937	ATTORNEY'S DOCKET NUMBER X-11634
--	--	--

17. <input checked="" type="checkbox"/> The following fees are submitted:	CALCULATIONS PTO USE ONLY																																																					
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):																																																						
Search Report has been prepared by the EPO or JPO..... \$840.00																																																						
International preliminary examination fee paid to USPTO (37 CFR 1.482)..... \$670.00																																																						
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))..... \$760.00																																																						
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$970.00																																																						
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00																																																						
ENTER APPROPRIATE BASIC FEE AMOUNT =	\$ 670.00																																																					
Surcharge of \$130.00 for furnishing the oath or declaration later than <u> 20 </u> <u> 30 </u> months from the earliest claimed priority date (37 CFR 1.492(e)).	\$																																																					
<table border="1"> <thead> <tr> <th>CLAIMS</th> <th>NUMBER FILED</th> <th>NUMBER EXTRA</th> <th>RATE</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>8 - 20=</td> <td>0</td> <td>X \$18.00</td> </tr> <tr> <td>Independent claims</td> <td>2 - 3=</td> <td>0</td> <td>X \$78.00</td> </tr> <tr> <td colspan="3">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ \$260.00</td> </tr> <tr> <td colspan="3">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$ 670.00</td> </tr> <tr> <td colspan="3">Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).</td> <td>\$</td> </tr> <tr> <td colspan="3">SUBTOTAL =</td> <td>\$ 670.00</td> </tr> <tr> <td colspan="3">Processing fee of \$130.00 for furnishing English translation later than <u> 20 </u> <u> 30 </u> months from the earliest claimed priority date (37 CFR 1.492(f)).</td> <td>\$</td> </tr> <tr> <td colspan="3">TOTAL NATIONAL FEE =</td> <td>\$ 670.00</td> </tr> <tr> <td colspan="3">Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property</td> <td>\$</td> </tr> <tr> <td colspan="3">TOTAL FEES ENCLOSED =</td> <td>\$ 670.00</td> </tr> <tr> <td colspan="3"></td> <td>Amount to be refunded \$</td> </tr> <tr> <td colspan="3"></td> <td>charged \$</td> </tr> </tbody></table>	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total claims	8 - 20=	0	X \$18.00	Independent claims	2 - 3=	0	X \$78.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	TOTAL OF ABOVE CALCULATIONS =			\$ 670.00	Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).			\$	SUBTOTAL =			\$ 670.00	Processing fee of \$130.00 for furnishing English translation later than <u> 20 </u> <u> 30 </u> months from the earliest claimed priority date (37 CFR 1.492(f)).			\$	TOTAL NATIONAL FEE =			\$ 670.00	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property			\$	TOTAL FEES ENCLOSED =			\$ 670.00				Amount to be refunded \$				charged \$		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																																																			
Total claims	8 - 20=	0	X \$18.00																																																			
Independent claims	2 - 3=	0	X \$78.00																																																			
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00																																																			
TOTAL OF ABOVE CALCULATIONS =			\$ 670.00																																																			
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).			\$																																																			
SUBTOTAL =			\$ 670.00																																																			
Processing fee of \$130.00 for furnishing English translation later than <u> 20 </u> <u> 30 </u> months from the earliest claimed priority date (37 CFR 1.492(f)).			\$																																																			
TOTAL NATIONAL FEE =			\$ 670.00																																																			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property			\$																																																			
TOTAL FEES ENCLOSED =			\$ 670.00																																																			
			Amount to be refunded \$																																																			
			charged \$																																																			

- a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 05-0840 in the amount of **\$ 670.00** to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 05-0840. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:
ELI LILLY AND COMPANY
PATENT DIVISION/BPB
LILLY CORPORATE CENTER

Brian P. Barrett
SIGNATURE

Brian P. Barrett
NAME

January 22, 2001
Date

39,597
REGISTRATION NUMBER

(317) 276-7243
TELEPHONE NUMBER

CRYOGRANULATION OF ACTIVATED PROTEIN C

This application claims priority of Provisional
5 Application Serial No. 60/094,969 filed July 31, 1998.

This invention relates to the bulk manufacturing
process of activated protein C.

Protein C is a serine protease and naturally occurring
10 anticoagulant that plays a role in the regulation of
hemostasis by inactivating Factors Va and VIIIa in the
coagulation cascade. Human protein C circulates as a 2-
chain zymogen which is activated *in vivo* by thrombin and
thrombomodulin on phospholipid surfaces resulting in
15 activated protein C (aPC). The protein C enzyme system
represents a major physiological mechanism of
anticoagulation.

Recombinant human protein C is generally produced by
mammalian cell culture and purified by conventional
20 chromatography techniques. When these techniques are
performed at a laboratory scale, the resulting solution of
aPC is readily handled and processed by standard techniques
such as freeze drying. For production on a commercial
scale, however, the aPC production and purification
25 procedure generates a large volume of solution which is
immediately shipped to formulation and filling operations in
sterile bags. This method of handling large volumes of aPC
is not desirable because the solution is neither stable nor
easily dispensed. Furthermore, the necessity to handle
30 large solutions of aPC links the schedule, scale, and site
of commercial purification operations to the scale,
schedule, and site of the commercial formulation fill/finish
operations.

-2-

A stable preformulation form of aPC is preferred. Freeze-drying usually is a viable option for rendering a protein in a bulk biological solution in the solid form as an amorphous powder. However, amorphous proteins can be unstable for extended periods. The large volumes of solution generated in the commercial manufacturing process renders freeze drying as an impractical technique due to the expense and the extended time needed to process the solution. Additionally, the freeze-dried protein can be fluffy, dusty, and difficult to handle as an amorphous solid powder (Akers and Schmidt, *BioPharm* 10(4):29-31, 1997).

Frozen solutions of aPC are not suitable for a commercial setting because containers freeze and thaw unevenly, generating concentration gradients and autoproteolysis. Freezing of large volumes of solution requires a significant amount of time and the resulting "blocks" of frozen solution are difficult to handle. Moreover, containers of frozen aPC are not readily dispensed for filling or sampling.

Therefore, commercial production of aPC generates a large volume of a biologically active solution that is difficult to process. A stable preformulation form is preferred to facilitate handling and to maintain the product integrity of the solution during the manufacturing process. Traditional "block" freezing or commercial freeze drying procedures are not practical and do not solve this problem. Thus, there remains the need to identify a stable, preformulation form of the aPC solution generated in the manufacturing process that is suitable for storage, handling, and recovery.

The present invention provides cryogranules of activated protein C. The invention further provides a process of preparing cryogranules which comprises providing an aqueous solution of activated protein C, dividing the aqueous solution of aPC into droplets, and freezing said droplets in liquid nitrogen forming cryogranules.

-3-

The invention further provides a process of thawing the cryogranules of activated protein C, adding a pharmaceutically acceptable excipient, dispensing the solution into unit dosage receptacles, and lyophilizing the solution.

For purposes of the present invention, as disclosed and claimed herein, the following terms are defined below.

aPC or activated protein C whether recombinant or plasma derived - aPC includes and is preferably human protein C although aPC may also include other species or derivatives having protein C proteolytic, amidolytic, esterolytic, and biological (anticoagulant or pro-fibrinolytic) activities. Examples of protein C derivatives are described by Gerlitz, *et al.*, U.S. Patent No. 5,453,373, and Foster, *et al.*, U.S. Patent No. 5,516,650, the entire teachings of which are hereby included by reference.

r-hPC - recombinant human protein C zymogen, produced in prokaryotic cells, eukaryotic cells or transgenic animals.

r-aPC - recombinant human activated protein C produced by activating r-hPC *in vitro* or by direct secretion of the activated form of protein C from procaryotic cells, eukaryotic cells, or transgenic animals [Cottingham, WO97/20043] including, for example, secretion from human kidney 293 cells as a zymogen then purified and activated by techniques well known to the skilled artisan demonstrated in Yan, U.S. Patent No. 4,981,952, the entire teachings of which are herein incorporated by reference.

Zymogen - refers to secreted, inactive forms, whether one chain or two chains of protein C.

Cryogranules - frozen, discrete granules from solutions or slurries of activated protein C formed after contact with a cryogenic material such as liquid nitrogen.

Pharmaceutical formulation - a formulation or solution that is appropriate to be given as a therapeutic agent.

Aqueous solution - a liquid solvent that contains water. Aqueous solutions may be comprised solely of water,

-4-

or may be comprised of water plus one or more miscible solvents, and may contain dissolved solutes such as sugars or other excipients. The more commonly-used miscible solvents are the short-chain organic alcohols, such as, methanol, ethanol, propanol, short-chain ketones, such as acetone, and polyalcohols, such as glycerol.

Pharmaceutically acceptable bulking agent - agents such as but not limited to sucrose, trehalose and raffinose which provide a pharmaceutically elegant formulation which has a uniform appearance and is readily solubilized when resuspended with the appropriate solute. A pharmaceutically elegant formulation is desired for parenteral administration.

The present invention provides a process for producing cryogranules of activated protein C. Cryogranules preserve the biological activity of aPC and are suitable for storage, handling, and recovery of aPC during the manufacturing process.

Preserving the biological activity of recombinantly produced proteins during the bulk manufacturing process and bulk distribution to product manufacturing facilities is a critical issue in the biotechnology process. Unlike most bulk manufacturing processes which prepare a solid bulk distribution form, proteins produced by recombinant technology, generate large volumes of solution during the cell culture and purification process. Generally, this bulk solution must be transported to formulation and filling operations. Bulk biological solutions are often frozen because of their instability in solution at refrigerated or higher temperatures. Nonetheless, freezing is slow and nonuniform and, in some cases, causes considerable degradation which may adversely affect product quality. Freeze-thaw procedures in recombinant protein manufacturing can denature and/or inactivate many enzymes. Redissolution of frozen proteins does not always readily occur. Therefore, traditional freezing of large volumes of solutions containing recombinant proteins is not only

-5-

unpredictable and generally results in a decrease in yield and a loss of activity of the protein but also results in a preformulation form that is problematic for formulation and filling operations. (Pikal, *BioPharm* 3(8):18-27, 1990; 5 Pikal, *Biopharm* 3(9):26-30, 1990).

Proteins often present unique stability problems when traditional methods of freezing or freeze-drying are utilized. Aggregation leading to insoluble protein is a common observation which can adversely affect enzymatic 10 activity. Furthermore, serine proteases such as aPC can autodegrade, leading to decreased functionality. Previous studies describing the production of aPC have not addressed the unique problems associated with commercial production, storage, and handling of the bulk protein substance (for 15 example, U.S. Patent Nos. 5,270,040, 5,550,036, 5,681,932 and Japanese patent application JP7165605). Therefore, the applicants are the first to provide a means of solving the problems of chemical and biological activity associated with the commercial production of recombinantly produced 20 activated protein C and have discovered that cryogranulation is superior to traditional freezing or freeze-drying in producing a stable bulk protein substance suitable for storage, handling, and recovery.

Generally, the aPC solution cryogranulated as described 25 herein comprises aPC and water. Preferably, the solution also includes other excipients including a pharmaceutically acceptable salt and a buffer. The cryogranulation solution contains up to 40 mg/ml aPC. Preferably, the cryogranulation solution contains about 1 mg/ml to about 30 30 mg/ml aPC. More preferably, the cryogranulation solution contains about 2.5 mg/ml to about 20 mg/ml aPC. The preferred concentration of aPC is 10 mg/ml.

Pharmaceutically acceptable salts used in the cryogranulation of aPC typically refers to a salt formed 35 between any one or more of the charged groups in the protein and any one or more physiologically-acceptable, non-toxic cations or anions. Organic and inorganic salts include, for

-6-

example, those prepared from acids such as hydrochloric, sulfuric, sulfonic, tartaric, fumaric, hydrobromic, glycolic, citric, maleic, phosphoric, succinic, acetic, nitric, benzoic, ascorbic, p-toluenesulfonic,

5 benzenesulfonic, naphthalenesulfonic, propionic, carbonic, and the like, or for example, ammonium, sodium, potassium, calcium, or magnesium. The preferred salt in the present invention is sodium chloride. Preferably, the sodium chloride concentration is about 150 mM to about 1000 mM.

10 More preferably, the sodium chloride concentration is about 325 mM to about 650 mM. The preferred sodium chloride concentration is 400 mM.

Representative buffer systems for controlling pH at a moderately acidic pH to a moderately basic pH include such
15 compounds as phosphate, acetate, citrate, arginine, TRIS, and histidine. "TRIS" refers to 2-amino-2-hydroxymethyl-1,3,-propanediol, and to any pharmacologically acceptable salt thereof. Other buffers that are physiologically acceptable, and that are suitable for controlling pH at the
20 desired level will be known to those of ordinary skill in the art. Preferred buffer systems include sodium citrate and sodium phosphate. The most preferred buffer is sodium citrate. The preferred molarity is about 10 mM to about 50 mM citrate. More preferably, the molarity is about 20 mM.
25 The preferred pH is between about pH 5.0 and about pH 7.0. More preferably the pH is between about pH 5.6 and about pH 6.4. The most preferred pH is about pH 6.0.

Therefore, the excipient free solution comprising
10 mg/ml aPC, 23.4 mg/ml (400 mM) sodium chloride, and 3.78
30 mg/ml (20 mM) citrate, pH 6.0, was found to be optimal for cryogranulation for the commercial formulation of aPC.

Cryogranulating aPC as described herein results in a stable preformulation protein substance suitable for storage, handling, and recovery. The process is high
35 yielding, and the product generated is not flocculent, is enzymatically stable when stored at -70°C, and is easily contained in a production setting.

-7-

The cryogranulation of aPC preferably employs a cryogranulation unit such as the 500S Cryogran Unit (IQF Inc., Ontario Canada) or other such units appreciated in the art. Optimal cryogranules are flowable, discrete frozen pellets. For example, if the droplets are too small a "spray" results in loss in yield or falling through the conveyor of the cryogranulation unit. If the drops are too large they can collide and clump forming a cryogranule "clot". Also, if the droplets are too large they do not freeze uniformly. Uniformity of the droplets and hence cryogranule size is a function of the flow rate of the process stream forming the droplets such as viscosity and/or surface tension. The preferred size of the cryogranules is about 2 mm to about 10 mm in diameter.

Cryogranules of aPC are generated by contacting droplets of aPC cryogranulation solution in liquid nitrogen or other freezing agents suitable for rapidly freezing the solution at temperatures from -40°C to -90°C. Discrete frozen pellets of aPC are produced during the residence time in which the cryogranulation solution is in contact with liquid nitrogen. The means to contact the aPC solution and the freezing agent is not critical to the present invention. Generally, the stream of liquid nitrogen and the frozen pellets are deposited onto a mesh conveyor belt that allows the liquid nitrogen to fall through and into a collection vessel. The frozen pellets of aPC are collected, transported into an insulated container and held below the glass point of the solution.

Properly formed cryogranules can be properly handled, such as scooping, weighing and separating them. Cryogranulation of aPC significantly facilitates the manufacturing process by bridging the interface between bulk and fill/finish manufacturing operations. Thus, cryogranulation offers significant advantages over alternative procedures available for the aPC production and purification process.

-8-

Preparation 1Preparation of Human Protein C

Recombinant human protein C (r-HPC) is produced in Human Kidney 293 cells by techniques well known to the skilled artisan such as those set forth in Yan, U.S. Patent No. 4,981,952, the entire teaching of which is herein incorporated by reference. The gene encoding human protein C is disclosed and claimed in Bang, et al., U.S. Patent No. 4,775,624, the entire teaching of which is incorporated herein by reference. The plasmid used to express human protein C in 293 cells is plasmid pLPC which is disclosed in Bang, et al., U.S. Patent No. 4,992,373 and Berg, et al., U.S. Patent No. 5,661,002, the entire teachings of which are incorporated herein by reference. The construction of plasmid pLPC is also described in European Patent Publication No. 0 445 939, and in Grinnell, et al., *Bio/Technology* 5:1189-1192, 1987, the teachings of which are also incorporated herein by reference. Briefly, the plasmid is transfected into 293 cells, then stable transformants are identified, subcultured and grown in serum-free media. After fermentation, cell-free medium is obtained by microfiltration.

The human protein C is separated from the culture fluid by an adaptation of the techniques of Yan, U.S. Patent No. 4,981,952, the entire teaching of which is herein incorporated by reference. The clarified medium is made 4 mM in EDTA before it is absorbed to an anion exchange resin (Fast-Flow Q, Pharmacia). After washing with 4 column volumes of 20 mM Tris, 200 mM NaCl, pH 7.4 and 2 column volumes of 20 mM Tris, 150 mM NaCl, pH 7.4, the bound recombinant human protein C zymogen is eluted with 20 mM Tris, 150 mM NaCl, 10 mM CaCl₂, pH 7.4. The eluted protein is greater than 95% pure after elution as judged by SDS-polyacrylamide gel electrophoresis.

Further purification of the protein is accomplished by making the protein 3 M in NaCl followed by adsorption to a hydrophobic interaction resin (Toyopearl Phenyl 650 M,

-9-

TosoHaas) equilibrated in 20 mM Tris, 3 M NaCl, 10 mM CaCl_2 , pH 7.4. After washing with 2 column volumes of equilibration buffer without CaCl_2 , the recombinant human protein C is eluted with 20 mM Tris, pH 7.4. The eluted protein is prepared for activation by removal of residual calcium. The recombinant human protein C is passed over a metal affinity column (Chelex-100, Bio-Rad) to remove calcium and again bound to an anion exchanger (Fast Flow Q, Pharmacia). Both of these columns are arranged in series and equilibrated in 20 mM Tris, 150 mM NaCl, 5 mM EDTA, pH 7.4. Following loading of the protein, the Chelex-100 column is washed with one column volume of the same buffer before disconnecting it from the series. The anion exchange column is washed with 3 column volumes of equilibration buffer before eluting the protein with 0.4 M NaCl, 20 mM Tris-acetate, pH 6.5. Protein concentrations of recombinant human protein C and recombinant activated protein C solutions are measured by UV 280 nm extinction $E_{0.1\%} = 1.81$ or 1.85, respectively.

Preparation 2

Activation of Recombinant Human Protein C

Bovine thrombin is coupled to Activated CH-Sepharose 4B (Pharmacia) in the presence of 50 mM HEPES, pH 7.5 at 4°C. The coupling reaction is done on resin already packed into a column using approximately 5000 units thrombin/ml resin. The thrombin solution is circulated through the column for approximately 3 hours before adding MEA to a concentration of 0.6 ml/l of circulating solution. The MEA-containing solution is circulated for an additional 10-12 hours to assure complete blockage of the unreacted amines on the resin. Following blocking, the thrombin-coupled resin is washed with 10 column volumes of 1 M NaCl, 20 mM Tris, pH 6.5 to remove all non-specifically bound protein, and is used in activation reactions after equilibrating in activation buffer.

-10-

Purified rHPC is made 5mM in EDTA (to chelate any residual calcium) and diluted to a concentration of 2 mg/ml with 20 mM Tris, pH 7.4 or 20 mM Tris-acetate, pH 6.5. This material is passed through a thrombin column equilibrated at 37°C with 50 mM NaCl and either 20 mM Tris pH 7.4 or 20 mM Tris-acetate pH 6.5. The flow rate is adjusted to allow for approximately 20 min. of contact time between the rHPC and thrombin resin. The effluent is collected and immediately assayed for amidolytic activity. If the material did not have a specific activity (amidolytic) comparable to an established standard of aPC, it is recycled over the thrombin column to activate the rHPC to completion. This is followed by 1:1 dilution of the material with 20 mM buffer as above, with a pH of either 7.4 or 6.5 to keep the aPC at lower concentrations while it awaited the next processing step.

Removal of leached thrombin from the aPC material is accomplished by binding the aPC to an anion exchange resin (Fast Flow Q, Pharmacia) equilibrated in activation buffer (either 20 mM Tris, pH 7.4 or 20 mM Tris-acetate, pH 6.5) with 150 mM NaCl. Thrombin does not interact with the anion exchange resin under these conditions, but passes through the column into the sample application effluent. Once the aPC is loaded onto the column, a 2-6 column volume wash with 20 mM equilibration buffer is done before eluting the bound aPC with a step elution using 0.4 M NaCl in either 5 mM Tris-acetate, pH 6.5 or 20 mM Tris, pH 7.4. Higher volume washes of the column facilitated more complete removal of the dodecapeptide.

The anticoagulant activity of activated protein C was determined by measuring the prolongation of the clotting time in the activated partial thromboplastin time (APTT) clotting assay. A standard curve was prepared in dilution buffer (1 mg/mL radioimmunoassay grade bovine serum albumin [BSA], 20 mM Tris, pH 7.4, 150 mM NaCl, 0.02% NaN₃) ranging in protein C concentration from 125-1000 ng/mL, while samples were prepared at several dilutions in this

-11-

concentration range. To each sample cuvette, 50 μ L of cold horse plasma and 50 μ L of reconstituted activated partial thromboplastin time reagent (APTT Reagent, Sigma) were added and incubated at 37°C for 5 min. After incubation, 50 μ L of the appropriate samples or standards were added to each cuvette. Dilution buffer was used in place of sample or standard to determine basal clotting time. The timer of the fibrometer (CoA Screener Hemostasis Analyzer, American Labor) was started immediately after the addition of 50 μ L 37°C 30 mM CaCl_2 to each sample or standard. Activated protein C concentration in samples are calculated from the linear regression equation of the standard curve. Clotting times reported here are the average of a minimum of three replicates, including standard curve samples.

Example 1

Production of Activated Protein C Cryogranules

A 500S Cryogran Unit (IQF Inc., Ontario Canada) is utilized for the cryogranulation of activated protein C. The 500s Cryogran Unit contains a 72 nozzle filling head with 15-18 gauge square-tipped needles, $\frac{1}{2}$ " long and operates at a liquid feed rate of approximately 15 ml/min per needle. A 12" wide liquid nitrogen river interfaces at the point of product entry, processing approximately 65 liters of cryogranulation solution per hour. Therefore, at 15 ml/min per needle and a 72 needle nozzle filling head, the total run time for one lot of 100 liters of solution is approximately 90 minutes. Thus, a cryogranulation solution comprised of 10 mg/ml aPC, 23.4 mg/ml (400mM) sodium chloride, and 3.78 mg/ml (20 mM) citrate, pH 6.0, is processed in the 500S Cryogran Unit to form droplets which are frozen into cryogranules as described.

Example 2

Stability Recombinant Human Activated Protein C

The stability of cryogranulated, recombinant human activated protein C (aPC) was monitored over a period of 34

-12-

weeks. The potency of aPC was monitored using the automated partial thromboplastin time (APTT) bioassay, and variant forms of the molecule resulting from proteolytic cleavage were monitored using the high-pressure liquid chromatography/mass spectrometry (HPLC/MS).

Cyogranulated aPC was produced as described in Example 1. These cryogranules were stored frozen at -70°C and samples were periodically removed for analysis. The following table indicates which of the above-mentioned procedures were used at the various time points of analysis:

Table 1

Analysis Timepoint (weeks)	0	22	28	29	33	34
N-terminal Degradation Products	<5 % *	<5 %	N/A	<5 %	6 %	N/A
Proteolytic Cleavage Products	<5 %	<5 %	N/A	<5 %	<5 %	N/A
Potency	382 U/mg	355 U/mg	484 U/mg	N/A	N/A	448 U/mg

N/A - data not available

The limit of quantitation (LOQ) for the HPLC/MS procedure is 5%, thus a value of "<5 %" is below the LOQ.

There is no evidence for an overall decrease in potency of the aPC cryogranule lot during the time of storage, and the percentages of proteolytic cleavage products did not increase during the time of storage. The percentage of N-terminal degradation products has increased above the limit of quantitation for the method at the 33-week time point, but the increase is not significant. Based on these three data sets, stability of aPC cryogranules has been demonstrated over 34 weeks when stored frozen at -70°C.

-13-

We Claim:

1. A method of processing an aqueous solution of
5 activated protein C into a state suitable for storage,
handling, and recovery, comprising the steps of:

(a) dividing the aqueous solution of activated
protein C into droplets;

(b) freezing said droplets into cryogranules.

10 2. The process of Claim 1 wherein the activated
protein C is human activated protein C.

15 3. The process of Claim 1 wherein the droplets are
frozen using liquid nitrogen.

4. The process of Claim 3 wherein the cryogranules are
about 2 mm to about 10 mm in diameter.

20 5. Cryogranules of activated protein C.

6. The cryogranules of Claim 5, wherein the activated
protein C is human activated protein C.

25 7. A process of preparing a lyophilized formulation of
aPC, which comprises:

(a) thawing the cryogranules to form a solution;

(b) optionally adding a pharmaceutically
acceptable bulking agent to said solution;

30 (c) dispensing said solution into unit dosage
receptacles;

(d) lyophilizing said solution.

35 8. The process of Claim 7, wherein the
pharmaceutically acceptable bulking agent is sucrose.

**DECLARATION FOR
UTILITY OR DESIGN
PATENT APPLICATION**

- ☒ Declaration Submitted with Initial Filing
☐ Declaration Submitted after Initial Filing

Attorney Docket Number	X-11634
First Named Inventor	Jeffrey Clayton Baker, et al.
COMPLETE IF KNOWN	
Application Number	
Filing Date	
Group Art Unit	
Examiner Name	

As a below named Inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole Inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the Invention entitled:

CRYOGRANULATION OF ACTIVATED PROTEIN C

the specification of which
☐ is attached hereto
OR

☒ was filed on 07/26/1999 as United States Application Number or PCT International
(MM/DD/YYYY)

Application Number PCT/US99/16937 and was amended on (if applicable).
(MM/DD/YYYY)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto:

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional applications(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.
60/094,969	07/31/1998	

DECLARATION

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Attorney Name	Reg. No.
Arvie J. Anderson	45,263
Lynn D. Apelgren	45,341
Robert A. Armitage	27,417
Brian P. Barrett	39,597
Michael T. Bates	34,121
Roger S. Benjamin	27,025
William R. Boudreaux	35,796
Steven P. Caltrider	36,467
Paul R. Cantrell	36,470
Charles E. Cohen	34,565
Robert A. Conrad	32,089
Donald L. Corneglio	30,741
Gregory A. Cox	P47,504
Paul R. Darkes	33,862
Paula K. Davis	P47,517
Elizabeth A. Dawalt	44,646
John C. Demeter	30,167
Manisha A. Desai	43,585
Jeanne Longo Feeney	35,134
Paul J. Gaylo	36,808
Francis O. Ginah	44,712
Amy E. Hamilton	33,894
Frederick D. Hunter	26,915
Thomas E. Jackson	33,064
Charles Joyner	30,466
Gerald P. Keleher	43,707
James J. Kelley	41,888

Attorney Name	Reg. No.
Paul C. Kimball	34,641
Paul J. Koivuniemi	31,533
Robert E. Lee	27,919
Kirby Lee	P47,744
James P. Leeds	35,241
Nelsen L. Lentz	38,537
Janet T. McClain	36,863
Douglas K. Norman	33,267
Aleen Palmberg	40,422
Raymond S. Parker, III	34,893
Thomas G. Plant	35,784
Edward Prein	37,212
James J. Sales	33,773
Michael J. Sayles	32,295
Robert L. Sharp	45,609
David M. Stemerick	40,187
Mark J. Stewart	43,936
Robert D. Titus	40,206
Robert C. Tucker	45,165
Tina M. Tucker	47,145
MaCharri Vorndran-Jones	36,711
Gilbert T. Voy	43,972
Andrea C. Walsh	34,988
Thomas D. Webster	39,872
Lawrence T. Welch	29,487
Alexander Wilson	P45,782

☐ Additional registered practitioner(s) named on a supplemental sheet attached hereto.

Direct all correspondence to:

Name	ELI LILLY AND COMPANY		
Address	ATTN: Brian P. Barrett		
Address	LILLY CORPORATE CENTER/DC1104		
City	INDIANAPOLIS	State	INDIANA
Country		Telephone	(317) 276-7243
		Fax	(317) 276-5172
		ZIP	46285

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A Petition has been filed for this unsigned inventor

Given Name	Jeffrey	Middle Name	Clayton	Family Name	Baker	Suffix	e.g. Jr.
------------	---------	-------------	---------	-------------	-------	--------	----------

Inventor's Signature	<i>Jeffrey Clayton Baker</i>	Date	1/19/01
----------------------	------------------------------	------	---------

Residence: City	Indianapolis	State	IN	Country	US	Citizenship	US
-----------------	--------------	-------	----	---------	----	-------------	----

Address	4430 North Pennsylvania Ave.
---------	------------------------------

Post Office Address	SAME AS ABOVE
---------------------	---------------

City	Indianapolis	State	IN	Zip	46205	Country	US
------	--------------	-------	----	-----	-------	---------	----

☒ Additional Inventors are being named on supplement sheet(s) attached hereto.

Please type a plus sign (+) inside this box. ☐

PTO/SB/01 (8-96) (MODIFIED)

Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

DECLARATION

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A Petition has been filed for this unsigned inventor					
Given Name	<i>Nancy</i>	Middle Name	<i>Delores</i>	Family Name	<i>Jones</i>	Suffix e.g. Jr.	
Inventor's Signature	<i>Nancy D. Jones</i>					Date	<i>1/19/01</i>
Residence: City	<i>Indianapolis</i>	State	<i>IN</i>	Country	<i>US</i>	Citizenship	<i>US USX</i>
Address	<i>3149 Midvale Drive</i>						
Post Office Address	<i>SAME AS ABOVE</i>						
City	<i>Indianapolis</i>	State	<i>IN</i>	Zip	<i>46222</i>	Country	<i>US</i>

Form 27-2-99